Literature DB >> 23519018

Multifunctional T-cell analyses to study response and progression in adoptive cell transfer immunotherapy.

Chao Ma1, Ann F Cheung, Thinle Chodon, Richard C Koya, Zhongqi Wu, Charles Ng, Earl Avramis, Alistair J Cochran, Owen N Witte, David Baltimore, Bartosz Chmielowski, James S Economou, Begonya Comin-Anduix, Antoni Ribas, James R Heath.   

Abstract

UNLABELLED: Adoptive cell transfer (ACT) of genetically engineered T cells expressing cancer-specific T-cell receptors (TCR) is a promising cancer treatment. Here, we investigate the in vivo functional activity and dynamics of the transferred cells by analyzing samples from 3 representative patients with melanoma enrolled in a clinical trial of ACT with TCR transgenic T cells targeted against the melanosomal antigen MART-1. The analyses included evaluating 19 secreted proteins from individual cells from phenotypically defined T-cell subpopulations, as well as the enumeration of T cells with TCR antigen specificity for 36 melanoma antigens. These analyses revealed the coordinated functional dynamics of the adoptively transferred, as well as endogenous, T cells, and the importance of highly functional T cells in dominating the antitumor immune response. This study highlights the need to develop approaches to maintaining antitumor T-cell functionality with the aim of increasing the long-term efficacy of TCR-engineered ACT immunotherapy. SIGNIFICANCE: A longitudinal functional study of adoptively transferred TCR–engineered lymphocytes yielded revealing snapshots for understanding the changes of antitumor responses over time in ACT immunotherapy of patients with advanced melanoma. ©2013 AACR.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23519018      PMCID: PMC3716460          DOI: 10.1158/2159-8290.CD-12-0383

Source DB:  PubMed          Journal:  Cancer Discov        ISSN: 2159-8274            Impact factor:   39.397


  36 in total

1.  The relationship of MHC-peptide binding and T cell activation probed using chemically defined MHC class II oligomers.

Authors:  J R Cochran; T O Cameron; L J Stern
Journal:  Immunity       Date:  2000-03       Impact factor: 31.745

2.  Two subsets of memory T lymphocytes with distinct homing potentials and effector functions.

Authors:  F Sallusto; D Lenig; R Förster; M Lipp; A Lanzavecchia
Journal:  Nature       Date:  1999-10-14       Impact factor: 49.962

3.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

Authors:  P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther
Journal:  J Natl Cancer Inst       Date:  2000-02-02       Impact factor: 13.506

4.  Cancer regression in patients after transfer of genetically engineered lymphocytes.

Authors:  Richard A Morgan; Mark E Dudley; John R Wunderlich; Marybeth S Hughes; James C Yang; Richard M Sherry; Richard E Royal; Suzanne L Topalian; Udai S Kammula; Nicholas P Restifo; Zhili Zheng; Azam Nahvi; Christiaan R de Vries; Linda J Rogers-Freezer; Sharon A Mavroukakis; Steven A Rosenberg
Journal:  Science       Date:  2006-08-31       Impact factor: 47.728

5.  Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206.

Authors:  Antoni Ribas; Luis H Camacho; Gabriel Lopez-Berestein; Dmitri Pavlov; Cecile A Bulanhagui; Robert Millham; Begoña Comin-Anduix; James M Reuben; Elisabeth Seja; Charla A Parker; Amarnath Sharma; John A Glaspy; Jesus Gomez-Navarro
Journal:  J Clin Oncol       Date:  2005-10-03       Impact factor: 44.544

6.  Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation.

Authors:  Jennifer Landsberg; Judith Kohlmeyer; Marcel Renn; Tobias Bald; Meri Rogava; Mira Cron; Martina Fatho; Volker Lennerz; Thomas Wölfel; Michael Hölzel; Thomas Tüting
Journal:  Nature       Date:  2012-10-10       Impact factor: 49.962

Review 7.  Loss of HLA class I antigens by melanoma cells: molecular mechanisms, functional significance and clinical relevance.

Authors:  S Ferrone; F M Marincola
Journal:  Immunol Today       Date:  1995-10

8.  Definition of an immunologic response using the major histocompatibility complex tetramer and enzyme-linked immunospot assays.

Authors:  Begoña Comin-Anduix; Antonio Gualberto; John A Glaspy; Elisabeth Seja; Maribel Ontiveros; Deborah L Reardon; Roberto Renteria; Brigitte Englahner; James S Economou; Jesus Gomez-Navarro; Antoni Ribas
Journal:  Clin Cancer Res       Date:  2006-01-01       Impact factor: 12.531

Review 9.  Determinant spreading and tumor responses after peptide-based cancer immunotherapy.

Authors:  Antoni Ribas; John M Timmerman; Lisa H Butterfield; James S Economou
Journal:  Trends Immunol       Date:  2003-02       Impact factor: 16.687

10.  HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells.

Authors:  Michael R Betts; Martha C Nason; Sadie M West; Stephen C De Rosa; Stephen A Migueles; Jonathan Abraham; Michael M Lederman; Jose M Benito; Paul A Goepfert; Mark Connors; Mario Roederer; Richard A Koup
Journal:  Blood       Date:  2006-02-07       Impact factor: 22.113

View more
  60 in total

Review 1.  Nanotechnologies for biomedical science and translational medicine.

Authors:  James R Heath
Journal:  Proc Natl Acad Sci U S A       Date:  2015-11-24       Impact factor: 11.205

Review 2.  Smart CARs engineered for cancer immunotherapy.

Authors:  Saul J Priceman; Stephen J Forman; Christine E Brown
Journal:  Curr Opin Oncol       Date:  2015-11       Impact factor: 3.645

3.  A Pilot Trial of the Combination of Transgenic NY-ESO-1-reactive Adoptive Cellular Therapy with Dendritic Cell Vaccination with or without Ipilimumab.

Authors:  Theodore S Nowicki; Beata Berent-Maoz; Gardenia Cheung-Lau; Rong Rong Huang; Xiaoyan Wang; Jennifer Tsoi; Paula Kaplan-Lefko; Paula Cabrera; Justin Tran; Jia Pang; Mignonette Macabali; Ivan Perez Garcilazo; Ignacio Baselga Carretero; Anusha Kalbasi; Alistair J Cochran; Catherine S Grasso; Siwen Hu-Lieskovan; Bartosz Chmielowski; Begoña Comin-Anduix; Arun Singh; Antoni Ribas
Journal:  Clin Cancer Res       Date:  2018-12-20       Impact factor: 12.531

4.  CD29 identifies IFN-γ-producing human CD8+ T cells with an increased cytotoxic potential.

Authors:  Benoît P Nicolet; Aurélie Guislain; Floris P J van Alphen; Raquel Gomez-Eerland; Ton N M Schumacher; Maartje van den Biggelaar; Monika C Wolkers
Journal:  Proc Natl Acad Sci U S A       Date:  2020-03-11       Impact factor: 11.205

5.  Multiplexed profiling of single-cell extracellular vesicles secretion.

Authors:  Yahui Ji; Dongyuan Qi; Linmei Li; Haoran Su; Xiaojie Li; Yong Luo; Bo Sun; Fuyin Zhang; Bingcheng Lin; Tingjiao Liu; Yao Lu
Journal:  Proc Natl Acad Sci U S A       Date:  2019-03-11       Impact factor: 11.205

Review 6.  Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy.

Authors:  Padmanee Sharma; Siwen Hu-Lieskovan; Jennifer A Wargo; Antoni Ribas
Journal:  Cell       Date:  2017-02-09       Impact factor: 41.582

7.  Twelve-year survival and immune correlates in dendritic cell-vaccinated melanoma patients.

Authors:  Stefanie Gross; Michael Erdmann; Ina Haendle; Steve Voland; Thomas Berger; Erwin Schultz; Erwin Strasser; Peter Dankerl; Rolf Janka; Stefan Schliep; Lucie Heinzerling; Karl Sotlar; Pierre Coulie; Gerold Schuler; Beatrice Schuler-Thurner
Journal:  JCI Insight       Date:  2017-04-20

Review 8.  Hematopoietic stem cells for cancer immunotherapy.

Authors:  Eric Gschweng; Satiro De Oliveira; Donald B Kohn
Journal:  Immunol Rev       Date:  2014-01       Impact factor: 12.988

9.  Persistent Polyfunctional Chimeric Antigen Receptor T Cells That Target Glypican 3 Eliminate Orthotopic Hepatocellular Carcinomas in Mice.

Authors:  Dan Li; Nan Li; Yi-Fan Zhang; Haiying Fu; Mingqian Feng; Dina Schneider; Ling Su; Xiaolin Wu; Jing Zhou; Sean Mackay; Josh Kramer; Zhijian Duan; Hongjia Yang; Aarti Kolluri; Alissa M Hummer; Madeline B Torres; Hu Zhu; Matthew D Hall; Xiaoling Luo; Jinqiu Chen; Qun Wang; Daniel Abate-Daga; Boro Dropublic; Stephen M Hewitt; Rimas J Orentas; Tim F Greten; Mitchell Ho
Journal:  Gastroenterology       Date:  2020-02-12       Impact factor: 22.682

10.  Effects of MAPK and PI3K pathways on PD-L1 expression in melanoma.

Authors:  Mohammad Atefi; Earl Avramis; Amanda Lassen; Deborah J L Wong; Lidia Robert; David Foulad; Michael Cerniglia; Bjoern Titz; Thinle Chodon; Thomas G Graeber; Begonya Comin-Anduix; Antoni Ribas
Journal:  Clin Cancer Res       Date:  2014-05-08       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.